Country, sex, edss change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Meyniel, Claire ^a,b   Spelman, Timothy ^a   Jokubaitis, Vilija G ^a   Trojano, Maria ^c   Izquierdo, Guillermo ^d   Grand'Maison, François ^e   Oreja Guevara, Celia ^f   Boz, Cavit ^g   Lugaresi, Alessandra ^h   Girard, Marc ⁱ   Grammond, Pierre ⁱ   Iuliano, Gerardo ^j   Fiol, Marcela ^k   Cabrera Gomez, Jose Antonio ^l   Fernandez Bolanos, Ricardo ^d   Giuliani, Giorgio ^m   Lechner Scott, Jeannette ⁿ   Cristiano, Edgardo ^o   Herbert, Joseph ^p   Petkovska Boskova, Tatjana ^q   Bergamaschi, Roberto ^r   van Pesch, Vincent ^s   Moore, Fraser ^t   Vella, Norbert ^u   Slee, Mark ^v   Santiago, Vetere ^w   Barnett, Michael ^x   Havrdova, Eva ^y   Young, Carolyn ^z   Sirbu, Carmen Adella ^aa   Tanner, Mary ^a   Rutherford, Michelle ^a   Butzkueven, Helmut ^a,ab,ac   Paolicelli, D ^ad   Lucchese, G ^ad   Iaffaldano, P ^ad   Marriott, M ^ad   Kilpatrick, T ^ad   King, J ^ad   Van der Walt, A ^ad   Haartsen, J ^ad   Skibina, O ^ad   Zwanikken, C ^ad   De Luca, Giovanna ^ad   Di Tommaso, V ^ad   Travaglini, D ^ad   Pietrolongo, E ^ad   di Ioia, M ^ad   Farina, D ^ad   Duquette, P ^ad   Petersen, T ^ad   Hupperts, R ^ad   Correale, J ^ad   Ysrraelit, C ^ad   Cartechini, E ^ad   Pucci, E ^ad   Williams, D ^ad   Dark, L ^ad   Verhuel, F ^ad   Vella, M ^ad   Saladino, M L ^ad   Paine, M ^ad   Shaw, C ^ad   more..

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF BARI   (Italy)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e Clinique Neuro Rive Sud   (Canada)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^h UNIVERSITY OF CHIETI   (Italy)

ⁱ Hotel Dieu de Levis Hospital   (Canada)

^j Ospedali Riuniti di Salerno   (Italy)

^k FLENI   (Argentina)

^l CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^m Ospedale di Macerata   (Italy)

ⁿ JOHN HUNTER HOSPITAL   (Australia)

^o HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^p NYU HOSPITAL FOR JOINT DISEASES   (United States)

^q Clinic of Neurology Clinical Center   (Macedonia)

^r C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^s CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^t MCGILL UNIVERSITY   (Canada)

^u MATER DEI HOSPITAL   (Malta)

^v FLINDERS UNIVERSITY   (Australia)

^w HIGA Gral   (Argentina)

^x UNIVERSITY OF SYDNEY   (Australia)

^y CHARLES UNIVERSITY   (Czech Republic)

^z WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^aa Central Military Hospital Bucharest   (Romania)

^ab UNIVERSITY OF MELBOURNE   (Australia)

^ac MONASH UNIVERSITY   (Australia)

^ad Monash University ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE;

ADULT; ARTICLE; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ETHNIC GROUP; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MSBASE INCIDENT STUDY; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTION; RELAPSE; SEX DIFFERENCE; SURVIVAL; TREATMENT WITHDRAWAL; TYPES OF STUDY;

EID: 84863093161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038661     Document Type: Article

References (27)

1. Brodsky M, Nazarian S, Orengo-Nania S, Hutton GJ, Buckley EG, et al. (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65: 727-732.
2. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, et al. (2004) Interferon β-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364: 1489-1496.
3. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle, et al, (2000) Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898-904.
4. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, et al. (2006) IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66: 678-684.
5. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Early Treatment of Multiple Sclerosis Study Group. Lancet 357: 1576-1582.
6. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, et al. (2006) Treatment with interferon β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7): 1242-1249.
7. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, et al. (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374: 1503-1511.
8. Reynolds MW, Stephen R, Seaman C, Rajagopalan K, (2010) Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 26: 663-674.
9. Mohr DC, Goodkin DE, Masuoka L, Dick LP, Russo D, et al. (1999) Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis.Mult Scler 5: 192-197.
10. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP, (2008) Long-term adherence to interferon β-therapy in relapsing-remitting multiple sclerosis. Eur Neurol 59: 131-135.
11. Ruggieri RM, Settipani N, Viviano L, Attanasio M, Giglia L, et al. (2003) Long-term interferon-β-treatment for multiple sclerosis. Neurol Sci 24: 361-364.
12. Kleinman NL, Beren IA, Rajagopalan K, Brook RA, (2010) Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Econ 13: 633-640.
13. Río J, Porcel J, Téllez N, Sánchez-Betancourt A, Tintoré M, et al. (2005) Factors related with treatment adherence to interferon β-and glatiramer acetate therapy in multiple sclerosis. Mult Scler 11: 306-309.
14. Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, et al. (2006) MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 12: 769-774.
15. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58: 840-846.
16. Kurtzke JF, (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33: 1444-1452.
17. Hurwitz BJ, (2011) Registry studies of long-term multiple sclerosis outcomes description of key registries. Neurology 76: S3-S6.
18. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ, (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55: 671-676.
19. Brønnum-Hansen H, Koch-Henriksen N, Hyllested K, (1994) Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 44: 1901-1907.
20. Tremlett HL, Oger J, (2003) Interrupted therapy: stopping and switching of the β-interferons prescribed for MS. Neurology 61: 551-554.
21. Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, et al. (2003) A post-marketing study on interferon β-1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74: 1689-1692.
22. Costello K, Kennedy P, Scanzillo J, (2008) Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 10: 225.
23. Ross AP, (2008) Tolerability, adherence, and patient outcomes. Neurology 71: S21-S23.
24. Heesen C, Kasper J, Segal J, Köpke S, Mühlhauser I, (2004) Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. Mult Scler. 10(6): 643-650.
25. Giordano A, Mattarozzi K, Pucci E, Leone M, Casini F, et al. (2008) Participation in medical decision-making: Attitudes of Italians with multiple sclerosis. J Neurol Sci pp. 86-91.
26. Arbizu T, Alvarez-Cermeño JC, Decap G, Fernández O, Uría DF, et al. (2000) Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 102: 209-217.
27. Miller DH, (2004) Brain atrophy, interferon beta, and treatment trials in multiple sclerosis. Lancet 364: 1463-1464.